Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20586088 | 1.00 | ALDH1A1 (0.50) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL19003501 | 0.79 | NPC1 (0.45) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL11637321 | 0.77 | SMN1; SMN2 (0.45) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL11634609 | 0.77 | SMN1; SMN2 (0.45) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL11634606 | 0.77 | SMN1; SMN2 (0.45) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL18992193 | 0.76 | TDP1 (0.43) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL18992194 | 0.76 | TDP1 (0.43) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL8706099 | 0.76 | MEN1 (0.46) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL14194422 | 0.73 | ALDH1A1 (0.56) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL8114454 | 0.73 | ALDH1A1 (0.56) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11485987-B2 | Methods for inducing bioorthogonal reactivity | UNIVERSITY OF DELAWARE (US) | 2022-11-01 | — | — | US | disclosed |
| US-20210164005-A1 | METHODS FOR INDUCING BIOORTHOGONAL REACTIVITY | UNIVERSITY OF DELAWARE (US) | 2021-06-03 | — | — | US | disclosed |
| US-10875840-B2 | Methods for inducing bioorthogonal reactivity | UNIVERSITY OF DELAWARE (US) | 2020-12-29 | — | — | US | disclosed |
| US-20180362504-A1 | METHODS FOR INDUCING BIOORTHOGONAL REACTIVITY | UNIVERSITY OF DELAWARE (US) | 2018-12-20 | — | — | US | disclosed |
| WO-2017106427-A1 | METHODS FOR INDUCING BIOORTHOGONAL REACTIVITY | FOX JOSEPH (US) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180362504-A1 | METHODS FOR INDUCING BIOORTHOGONAL REACTIVITY | CBR1, CBR3, DUOX1 | ALDH1A1 200/4885MAPT 3213/4885SMN1; SMN2 4820/4885 |
| US-10875840-B2 | Methods for inducing bioorthogonal reactivity | CBR1, CBR3, DUOX1 | ALDH1A1 204/4885MAPT 3220/4885SMN1; SMN2 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.